Clinical trials: Advanced
Head and Neck Squamous Cell Carcinoma
Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma
Multi-center, open-label, non-randomized, non-comparative two-cohort study for patients with locally-advanced squamous cell carcinoma arising from the larynx, hypopharynx, oropharynx (Stage III, IVA and IVB according to 8th…
- Trial name
- RADIAN (NCT05784012)
- Testing
- Dostarlimab, Niraparib, cisplatin plus radiotherapy
- Where
- 7 sites in Spain
- Volunteers
- 34 people
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Chondrosarcoma
A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)
This is a multicenter, open-label, Phase II trial designed to evaluate the efficacy and safety of PRO95780 when given as a single agent in patients with advanced chondrosarcoma.
- Trial name
- NCT00543712
- Testing
- PRO95780
- Where
- 4 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Genentech, Inc.
Neurocognitive
Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI
This is a prospective, randomised, positive-controlled, study to assess the neurocognitive function of upfront Osimertinib compared to whole-brain irradiation (WBI) plus Osimertinib in EGFR-mutant (Ex 19Del and L858R) NSCLC…
- Trial name
- NCT04829019
- Testing
- Osimertinib and whole-brain irradiation, Osimertinib
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Sun Yat-sen University
Metastatic Small Intestinal Adenocarcinoma, Recurrent Small Intestinal Carcinoma
Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
This phase II trial studies how well pembrolizumab works in treating patients with small bowel adenocarcinoma that has spread to other places in the body or that cannot be removed by surgery.
- Conditions
- Metastatic Small Intestinal Adenocarcinoma, Recurrent Small Intestinal Carcinoma, Unresectable Small Intestinal Carcinoma
- Trial name
- NCT02949219
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 41 people
- Sponsor
- Academic and Community Cancer Research United
Breast Cancer, Advanced Breast Cancer
Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer
The purpose of this study is to evaluate use of lovastatin, a drug that may lower CAV-1 levels, in order to increase HER2 expression on cells and enhance the uptake and efficacy of trastuzumab deruxtecan (T-DXd) in HER2-low and…
- Conditions
- Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT07619365
- Testing
- Trastuzumab deruxtecan, Lovastatin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Washington University School of Medicine
Pancreas Cancer
To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas
A dose escalation trial to assess the safety of plerixafor in patients with advanced pancreatic, high grade serous ovarian and colorectal cancer.
- Trial name
- NCT03277209
- Testing
- Plerixafor
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 2 people
- Sponsor
- Weill Medical College of Cornell University
Unresectable Gastric Cancer
A Retrospective Study of Immunotherapy in Conversion Therapy of Unresectable Gastric Cancer
This study was an observational, non-interventional, multicenter retrospective study to evaluate the feasibility and safety of sintilimab combined with chemotherapy (SOX or PS) in the clinical practice of unresectable locally…
- Trial name
- NCT05385809
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma (HCC)
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
Study Design: This is a pilot study with a single arm in a single centre assessing safety and efficacy of durvalumab in combination with bevacizumab and HAIC followed by SBRT.
- Trial name
- NCT07012798
- Testing
- Durvalumab, Bevacizumab, HAIC of FOLFOX
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Melanoma, Non Small Cell Lung Cancer
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, High Grade Serous Adenocarcinoma of Ovary
- Trial name
- PRESERVE-009 (NCT05858736)
- Testing
- AI-061
- Where
- 5 sites in Australia
- Volunteers
- 18 people
- Sponsor
- OncoC4, Inc.
Gingival Recession Generalized Moderate, Gingival Recession Localized Moderate
Comparing CAF and TCAF With Soft Tissue Grafting for Treating Multiple Recessions in the Maxilla.
Multiple techniques can be used for recession coverage. The most common techniques are: tunnel technique (T), coronally advanced flap (CAF) or a combination of both (TCAF).
- Conditions
- Gingival Recession Generalized Moderate, Gingival Recession Localized Moderate, Gingival Recession, Generalized, Gingival Recession, Localized
- Trial name
- NCT07158528
- Testing
- coronally advanced flap with connective tissue graft, tunneled coronally advanced flap with a connective tissue graft
- Where
- Belgium
- Volunteers
- 34 people
- Sponsor
- University Hospital, Ghent
Neoplasms, Solid Tumors
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors
This is a Phase 1 dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of BMS-754807 in patients with advanced or metastatic solid tumors.
- Conditions
- Neoplasms, Solid Tumors, Metastases
- Trial name
- NCT00569036
- Testing
- BMS-754807
- Where
- 5 sites in Australia
- Volunteers
- 63 people
- Sponsor
- Bristol-Myers Squibb
Advanced Liver Cancers
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available…
- Trial name
- MORPHEUS-LIVER (NCT04524871)
- Testing
- Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab
- Where
- 32 sites in United States, China and 5 more
- Volunteers
- 518 people
- Sponsor
- Hoffmann-La Roche
Cancer of Head and Neck
Single-arm Phase II Study of NDURE for Patients With HNC
This study will evaluate whether a new patient navigation intervention can decrease delays starting post-operative radiation therapy after surgery for white and African-American head and neck cancer patients.
- Trial name
- NDURE (NCT03821064)
- Testing
- Patient Navigation
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Medical University of South Carolina
Non-Small Cell Lung Cancer
Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior Chemotherapy
This study intends to describe the real-life effectiveness and safety of nivolumab in advanced NSCLC patients in Germany, as well as the patient profile, pattern of use and the quality of life.
- Trial name
- ENLARGE-Lung (NCT02910999)
- Where
- Germany
- Volunteers
- 868 people
- Sponsor
- Bristol-Myers Squibb
Pancreatic Cancer, Locally Advanced Pancreatic Cancer
Divestment for Artery-involved Pancreatic Cancer
Pancreatic cancer is the most lethal malignancy of human being. Surgery is the only potential cure of pancreatic cancer. The invasion of major abdominal arteries is one of the most important factor restricting surgical…
- Conditions
- Pancreatic Cancer, Locally Advanced Pancreatic Cancer, Neoadjuvant Therapy, Borderline Resectable Pancreatic Cancer
- Trial name
- NCT03443921
- Testing
- Artery Divestment Technique, Nab-paclitaxel
- Where
- China
- Volunteers
- 122 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Advanced and Metastatic Breast Cancer
Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer
This dose finding/extension study was designed originally to consist of three parts: Part A was intended to identify the MTD of the AZD2014/ palbociclib combination on a background of fulvestrant (referred to as the triplet) in…
- Trial name
- PASTOR (NCT02599714)
- Testing
- AZD2014, Palbociclib, Fulvestrant
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Melanoma
The Response of Serum 25-Hydroxyvitamin D to Incidental Ultraviolet Light Exposure
1.1 To detect reproducible variations of serum 25-hydroxyvitamin D levels throughout the course of one year in relationship to objectively measured levels of ultraviolet exposure.
- Trial name
- NCT00832533
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- New Mexico Cancer Research Alliance
Altered Taste
TQ-PAL Development and Validation
Taste problems are common among patients with advanced cancer. These symptoms can affect the pleasure of eating and drinking, reduce dietary intake, cause low mood, and a lower quality of life.
- Trial name
- NCT06588933
- Testing
- completion of a questionnaire
- Where
- Ireland
- Volunteers
- 200 people
- Sponsor
- Prof Andrew Davies
Pancreas Cancer
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
The purpose of this research is to determine the benefit of two oral chemotherapy drugs, Vemurafenib and Sorafenib, in individuals with KRAS mutated pancreatic cancer who have progressed on standard chemotherapy.
- Trial name
- NCT05068752
- Testing
- Vemurafenib, Sorafenib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- HonorHealth Research Institute
Differentiated Thyroid Cancer (DTC)
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
The purpose of this study is to assess the efficacy and safety of dabrafenib in combination with trametinib for treating adult patients with locally advanced or metastatic Differentiated Thyroid Cancer (DTC) harboring the…
- Trial name
- NCT04940052
- Testing
- Dabrafenib, Trametinib
- Where
- 41 sites in United States, Argentina and 9 more
- Volunteers
- 153 people
- Sponsor
- Novartis Pharmaceuticals